All In MedTech

Device Trial Radar · NCT04598802

COvera in BRAnch Registry

A Physician-initiated, Multicentre, Ambispective, Observational Registry of Patients Undergoing Complex Aortic Procedures With the Use of the Bard Covera Plus (Tempe, Arizona, USA) Covered Self-expandable Stents

Last checked: Nov 20, 2026Latest source record: Nov 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

300

Actual

Start

Oct 16, 2020

Primary completion

Oct 30, 2022

Study completion Oct 30, 2022

Sponsor

Lead sponsor
IRCCS San RaffaeleAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 22, 2020

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the registry is to evaluate the peri-operative and short-, mid- and long-term outcomes of the Bard Covera Plus (Tempe, Arizona, USA) for the treatment of atherosclerotic aorto-iliac aneurysm in combination with a multibranched endograft

Conditions

  • Aneurysm

Interventions

  • covered stentDevice

    atherosclerotic aorto-iliac aneurysm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. technical successTime frame: 30 days
  2. Branch instabilityTime frame: 30 days
  3. Primary clinical successTime frame: 30 days

Locations

33 sites in 2 countries. Site status is shown where the registry gives one.

  • University Heart & Vascular Center

    Hamburg, Germany

  • Ludwig-Maximilians University Hospital

    Munich, Germany

  • Ospedale di Asti

    Asti, Italy

30 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.